Stellaromics
Stellaromics develops the Pyxa platform, the first commercially available system for 3D spatial multi-omic transcriptomic analysis in intact tissue up to 100 micrometers thick. The Boston-based company sells instruments, proprietary STARmap/SEDAL reagent kits, and spatial transcriptomics services to academic research institutions and biotech/pharma customers.
- Company typePrivate
- Founded2022
- HeadquartersNatick, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Stellaromics does
Stellaromics, Inc. is a privately held biotechnology company founded in 2022 and headquartered in Boston, Massachusetts, that develops and commercializes the Pyxa platform for true 3D spatial multi-omic analysis of intact, thick tissue. The platform is built on two proprietary chemistry pillars — STARmap (Spatially Resolved Transcriptomics by barcoded Amplification with Rendering) using SNAIL probe architecture, and SEDAL (Sequencing with Error-reduction by Dynamic Annealing and Ligation) — that together enable multiplexed RNA detection in tissue sections up to 100 micrometers thick, roughly an order of magnitude thicker than conventional 2D spatial biology methods. Pyxa integrates sample preparation, automated volumetric confocal imaging, and PyxaStudio data visualization into a single end-to-end workstation, with optional assays including RIBOmap (translatomics), STARmap PLUS (mRNA life cycle), and TEMPOmap (subcellular RNA kinetics). The scientific founders are Karl Deisseroth (Stanford) and Xiao Wang (Broad Institute / MIT), both widely recognized as originators of modern spatial biology methods.
The company's business model is a classic life-sciences instrument + consumables architecture: capital revenue from Pyxa instrument sales (now open for order with installations beginning in 2026), recurring revenue from proprietary reagent kits (Sample Prep, SEDAL, Buffer), 12-well plates, and custom gene panels, supplemented by fee-for-service spatial transcriptomics projects priced at approximately $60,000 for an 8-sample project. Go-to-market is enterprise field sales targeting academic research institutions (the primary segment) and biotech/pharma translational programs (a secondary segment), with strong event-driven presence at AGBT, Festival of Genomics, Neuroscience 2025, and the HCA General Meeting, and demand generation via a $60K-value Pyxa Project Grant program and an Early Access Program with limited-time introductory pricing through June 2026. The company has raised a $25 million Series A (Plaisance Capital Management lead, November 2023) and reports an additional $80 million round (Catalyst4 lead, February 2025) per company-published information, with a headcount in the 11-50 range and leadership built out for commercial scale-up including SVP Global Commercial Operations, SVP Product Development, and SVP Operations appointments in 2026.
Customer concentration is currently entirely academic across three beta installations (University of Glasgow, UC Irvine, Emory University) and reference relationships with Stanford, OHSU Vollum Institute, and Scripps Research. Operating geographies include the United States, the United Kingdom (via Glasgow), and grant eligibility extending to Australia and broader Europe. Stellaromics remains in early commercial phase: it formally launched Pyxa at AGBT in February 2026 and began first shipments in April 2026, meaning revenue generation is in its earliest stages while capital deployment is focused on commercial scale-up.
Stellaromics firmographics
Firmographics- Name
- Stellaromics
- Legal name
- Stellaromics, Inc.
- Website
- https://stellaromics.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Stellaromics develops the Pyxa platform, the first commercially available system for 3D spatial multi-omic transcriptomic analysis in intact tissue up to 100 micrometers thick. The Boston-based company sells instruments, proprietary STARmap/SEDAL reagent kits, and spatial transcriptomics services to academic research institutions and biotech/pharma customers.
- Ownership category
- akta.pro rank
Stellaromics industry classification
Industry- Product category
- Spatial Biology Instruments
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
- akta.pro secondary industries
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where Stellaromics is headquartered
LocationHeadquarters
- HQ city
- Natick
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Stellaromics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Pyxa Instrument Sales: Sale of the Pyxa instrument platform - the main hardware system comprising instrument, assay kits, plates, custom panel design, PyxaStudio data visualization software, and technical support. Now commercially available with orders being taken for installation in 2026.
- Reagents and Consumables: Ongoing sales of sample preparation kits (STARmap Sample Prep Kit for thin and thick tissue), Pyxa SEDAL Kits, Pyxa Buffer Kits, Pyxa 12-well Plates, and gene panel probes. These are recurring consumable purchases required for each experiment run on the platform.
- Custom Gene Panel Design: Custom panel design and synthesis services for gene lists beyond the standard mouse brain panel. Allows customers to target specific genes for their research applications.
- Research Services: Spatial transcriptomics services performed by Stellaromics on customer samples. The company performs tissue sectioning, sample preparation, imaging, and primary data analysis. Pricing indicates an 8-sample service project valued at approximately $60,000.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | One time | Pyxa Project Grant - Free 8-sample service project |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
Stellaromics product offering
Product offeringCore offering
Stellaromics develops and sells the Pyxa platform, an automated high-plex confocal spatial multi-omics system that generates single-cell maps of 3D gene expression in intact tissue sections up to 100 micrometers thick. The offering includes the Pyxa instrument, proprietary assay kits (STARmap Sample Prep Kit, Pyxa SEDAL Kit, Pyxa Buffer Kit), gene panels (off-the-shelf and custom), PyxaStudio visualization software, and research services performed on customer samples.
Product overview
Stellaromics offers the Pyxa™ platform—a unified spatial multi-omics system for True 3D™ analysis of thick tissue. The platform consists of the Pyxa instrument (automated confocal imaging system), assay kits (STARmap Sample Prep Kit, Pyxa SEDAL Kit, Pyxa Buffer Kit), gene panels (Mouse Brain Pan-Neural Gene Cell Typing Panel and Custom Gene Panels), and PyxaStudio data visualization software. Supported assay technologies include STARmap (transcriptomics), RIBOmap (translatomics), STARmap PLUS (mRNA life cycle profiling), and TEMPOmap (temporal kinetics). The platform analyzes tissue sections 20-100 micrometers thick—up to 20 times thicker than conventional 2D spatial methods—preserving native cellular architecture for comprehensive 3D spatial analysis.
Differentiator
Problem solved
Functional benefit
Brands
- Pyxa™: The first commercially available platform for multiplexed 3D spatial transcriptomics in intact tissue up to 100 micrometers thick, enabling researchers to analyze tissue architecture in three dimensions with subcellular detail
- PyxaStudio™
- True 3D™
Products and services
- Pyxa 3D Spatial Multi-Omics Platform Automated, high-plex confocal spatial platform that delivers single-cell maps of 3D gene expression in thick tissue sections up to 100 micrometers thick. End-to-end system combining sample preparation, volumetric confocal imaging, and data analysis/visualization for academic research institutions and biotech/pharma teams.
- PyxaStudio Data Visualization Software Dedicated 3D data visualization software bundled with the Pyxa instrument that lets users navigate 3D tissue architecture from broad cellular organization down to subcellular transcript localization, including features for spatial distribution analysis, UMAP/spatial subselection, and bookmarking of cells and neighborhoods.
- STARmap Sample Prep Kit Sample preparation kit for the STARmap protocol, available in 4-well Thin (20 micron) and 4-well Thick (100 micron) formats for processing tissue on the Pyxa system.
- Pyxa SEDAL Kit Sequencing reagent kit using SEDAL (Sequencing with Error-reduction by Dynamic Annealing and Ligation) chemistry for decoding bases and converting sequence information into fluorescence signals; available in Thin and Thick formats.
- Pyxa Buffer Kit Buffer kit supporting Pyxa system processing, available in 4-well Thin and Thick formats.
- Pyxa 12-Well Plate 12-well microplate consumable compatible with the high-throughput Pyxa workflow, allowing up to 12 wells to be processed simultaneously.
- Mouse Brain Pan-Neural Gene Cell Typing Panel Off-the-shelf gene panel for mouse brain tissue analysis, enabling targeted spatial transcriptomics profiling for neuroscience research.
- Custom Gene Panels Custom panel design and synthesis service that targets specific genes and tissue types beyond Stellaromics' standard panels.
- Pyxa Research Services Fee-for-service spatial transcriptomics offering in which Stellaromics performs tissue sectioning, sample preparation, imaging, and primary data analysis on customer samples shipped to the Boston HQ. An 8-sample service project is valued at approximately $60,000.
Quantifiable outcome
- Tissue sections up to 100 micrometers thick - up to 20 times thicker than conventional platforms
- +2 more outcomes
Companies that use Stellaromics
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles2 records
Stellaromics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Stellaromics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- University of GlasgowcoreBeta testing site for Pyxa platform and first installation site for Pyxa 3D spatial transcriptomics system in Europe. Professor Nigel Jamieson's lab uses the platform for tumor microenvironment research on colorectal liver metastasis and hepatocellular carcinoma.
- University of California IrvinecoreFirst U.S. installation site for Pyxa 3D spatial transcriptomics system. Dr. Rui Chen's lab uses the platform for Human Cell Atlas initiative research on human sensory systems and eye mapping.
- Emory University School of MedicinecoreBeta testing site for Pyxa 3D spatial transcriptomics platform as part of expanded beta program. Part of broader academic collaboration for platform validation.
- Michael J. Fox FoundationminorCharitable partnership supporting Parkinson's Disease research, aligning with Stellaromics' scientific foundation in neuroscience and 'Work With Purpose' company value. The foundation's mission to cure Parkinson's Disease complements Stellaromics' spatial omics technology for brain research.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Stellaromics competitors and assessment
Company assessmentDirect peers
- Standard BioTools (formerly Fluidigm): Standard BioTools offers the Hyperion Imaging System for imaging mass cytometry and the SomaScan proteomics platform, both serving multi-omic tissue analysis in academic and pharma research. Comparable to Pyxa in spatial multi-omics instrumentation.
- Akoya Biosciences: Akoya offers the PhenoCycler (formerly CODEX) platform for spatial phenomics and the PhenoImager HT for high-throughput tissue imaging. Comparable to Pyxa in instrument-based spatial biology serving translational research and immuno-oncology workflows.
- Resolve Biosciences: Resolve Biosciences offers the Molecular Cartography platform for single-cell, subcellular spatial transcriptomics. Directly comparable as an emerging instrument-based spatial omics vendor competing for the same research dollars with single-molecule FISH-based chemistry.
- Ultivue: Ultivue provides antibody-based spatial proteomics and transcriptomics services and reagents for tissue analysis. Comparable to Stellaromics in serving academic and pharma spatial omics needs, though focused more on proteomics than transcriptomics.
- Vizgen: Vizgen commercializes MERFISH-based spatial transcriptomics instruments for single-cell and subcellular gene expression analysis in tissue. Directly comparable to Pyxa in product category (multiplexed spatial transcriptomics instruments) and customer base (academic and translational research).
- NanoString Technologies (now part of Bruker): NanoString's CosMx Spatial Molecular Imager and GeoMx Digital Spatial Profiler are leading spatial multi-omics platforms serving the same academic and pharma research market as Pyxa. The merger with Bruker expanded the commercial footprint, making it a more entrenched competitor.
- 10x Genomics: 10x Genomics is the dominant spatial biology player with Xenium (in situ) and Visium (spatial transcriptomics) platforms. Directly comparable to Stellaromics' Pyxa in target customers (academic research labs and pharma/biotech) and product category (spatial omics instruments with consumables), though currently focused on 2D workflows.
Broad incumbents
- Bruker Corporation: Bruker is a large analytical instruments manufacturer that acquired NanoString to expand into spatial biology. Comparable to Stellaromics in providing mass spectrometry and spatial omics instrumentation to research customers, though as a much broader portfolio company.
Emerging players
- RareCyte: RareCyte offers the Orion spatial biology platform for high-plex, single-cell spatial biomarker analysis in tissue. Comparable to Pyxa in instrument-based spatial multi-omics for translational and pharma research, though smaller and more niche.
- Ionpath (MIBIscope): Ionpath develops MIBIscope (Multiplexed Ion Beam Imaging) for high-plex spatial proteomics in tissue. Comparable to Pyxa as an emerging instrument vendor serving translational spatial biology research with multiplexed tissue analysis capability.
Market position
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Stellaromics social profiles
Digital presenceStellaromics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stellaromics leadership team
Management profileNumber of profiles
Profiles15 records
Stellaromics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stellaromics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stellaromics
What does Stellaromics do?
Stellaromics develops and sells the Pyxa platform, an automated high-plex confocal spatial multi-omics system that generates single-cell maps of 3D gene expression in intact tissue sections up to 100 micrometers thick. The offering includes the Pyxa instrument, proprietary assay kits (STARmap Sample Prep Kit, Pyxa SEDAL Kit, Pyxa Buffer Kit), gene panels (off-the-shelf and custom), PyxaStudio visualization software, and research services performed on customer samples.
Is Stellaromics a public or private company?
Stellaromics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Stellaromics founded?
Stellaromics was founded in 2022. It employs 51 to 100 people.
Where is Stellaromics based?
Stellaromics is headquartered in Natick, United States, in the North America region.
How does Stellaromics make money?
Four revenue lines are on record. Pyxa Instrument Sales are the primary driver. The others are reagents and Consumables, custom Gene Panel Design and research Services.
Who are Stellaromics's main competitors?
Direct peers on record are Standard BioTools (formerly Fluidigm), Akoya Biosciences, Resolve Biosciences, Ultivue, Vizgen, NanoString Technologies (now part of Bruker) and 10x Genomics. Bruker Corporation is listed as a broad incumbent. Emerging players are RareCyte and Ionpath (MIBIscope).
Does Stellaromics have an API?
No public API is recorded for Stellaromics.
What industry is Stellaromics in?
Stellaromics's product category is Spatial Biology Instruments. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 334516 and its SIC code is 3826.